Navigation Links
Isis Initiates Phase 1 Clinical Trial of SGLT2 Antisense Drug
Date:2/5/2009

expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis is a joint owner of Regulus Therapeutics Inc., a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

This press release includes forward-looking statements regarding Isis' discovery and development of drugs for metabolic diseases, and the potential of the antisense drug ISIS-SGLT2Rx to treat type 2 diabetes. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statem
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
3. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
4. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
5. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
6. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
7. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
8. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
9. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
10. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
11. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...ERDAM, November 30 Biopharmaceutic...first patients have been enrolled in its,multinati...e study is,designed to show reduction in transplan... an allogeneic stem cell transplantation with a mi...atients eligible for an allogeneic,stem cell trans...
(Date:11/30/2009)...lif., Nov. 30 BioMarin P...y that the Food and Drug Administration (FDA) has ...idine (3,4-DAP), amifampridine phosphate, for the ...yndrome (LEMS). 3,4-DAP has previously received o...er 2009, the Committee for Medicinal Products for ...
(Date:11/30/2009)...SHANGHAI, Nov. 30 /PRNewswire-Asia/ -- WuXi Pharma...echnology, and medical-device research and,develop...and the United States,announced that it had been ...2009 list for the fifth consecutive year. The list...ina,s technology, media, and telecommunications,in...
(Date:11/28/2009)... The Vanuatu National Advisory Committee on Cl...ommunication (SNC) Project in collaboration with t... Ltd. of New Zealand have generated preliminary cl...form the background for the country’s SNC re... on Climate Change (UNFCCC). , ...
Breaking Biology Technology:Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year 2Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 2Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 3Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 4
...therapies have been proposed for regenerative medi...e. However, the inability of stem cells to efficie...such as muscle, skin, blood vessels, bone or neuro...his therapy. , New research shows that delivering...ls via biodegradable microspheres enhances the eff...
... Baxter Healthcare Corporation,today announced it...eld,protective coating, the first needleless intra...coating, is now available for hospitals in the,Uni... been shown to kill on,average 99.9 percent or mor...agents) known to cause catheter-related bloodstrea...
...wire-FirstCall/ - Oncolytics Biotech Inc.,("Oncoly...tive interim,results from its U.K. combination REO...in Harrington of The Institute of Cancer Research,...al, presented the results today,at The 5th Annual ... (BSGT),in Edinburgh, Scotland., Four of the firs...
Other Biology Technology:Method to deliver molecules within embryonic stem cells improves differentiation 2Method to deliver molecules within embryonic stem cells improves differentiation 3Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 2Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 3Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 4Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial 2Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial 3
(Date:11/25/2009)... firefighters, police officers and ambulance worke...rade Center complex. They battled to save people f...vors, tackled fires and evacuated as many people a...ed 17,000 people. And making their jobs even harde...ed workers and their relatives jammed mobile netwo...
(Date:11/25/2009)...EMBER 25, 2009 Soil is the linchpin of the enviro...e meet. Despite that, many students see soil as "j...e. Soil science educators are challenged with the ...the critical importance of soil in the environment... earth science teachers at University of Nebraska-...
(Date:11/25/2009)...niversity assistant professors recently received f...to continue research beneficial to understanding t..., Christopher Blackwood, assistant professor in t...grants to support two separate research projects. ...ecomposer Communities and Functions from the Leaf ...
Breaking Biology News(10 mins):Magic box for mission impossible 2Magic box for mission impossible 3It's not just dirt! 2Kent State University professors focus research on the environment with grants totaling $890,000 2UAB researchers find TB prevention therapy is cost effective option 56588 1UAB researchers find TB prevention therapy is cost effective option 56588 2U of I acientist 3A Public policy should promote family mealtimes 56583 1U of I acientist 3A Public policy should promote family mealtimes 56583 2U of I acientist 3A Public policy should promote family mealtimes 56583 3Prototype NIST method detects and measures elusive hazards 9838 1Prototype NIST method detects and measures elusive hazards 9838 2
...and a socket, a nerve and a muscle fiber mesh at t...t al published in the Journal of Cell Biology re...laminin shapes both sides of the junction to ensur...8. , A neuromuscular junction, or synapse, in a ne...lar nerve terminal meeting a flat, oval structure ...
...t Johns Hopkins schools of Public Health and Medic...in the gene MYH9 that are associated with increase...SRD,) which is the near-loss of kidney function le...ted on the 22 chromosome, is the first gene identi... was published online September 14 in the journal ...
...ves Norman Dicks (D-WA) and Ralph Regula (R-OH) wi...ership Award at a Congressional Reception on Monda...d for their enduring support for the United States... Chairman of the House Appropriations Subcommittee... Representative Ralph Regula is former Chairman of...
Other Biology News:New gene variant identified for nondiabetic end stage renal disease in African-Americans 2USGS Coalition to honor Reps. Dicks, Regula with Leadership Award 2
...Microdissection (LCM) is the method of choice for ...issection is the only instrument to offer both LCM...y., UV Laser Cutting provides unprecedente...es and capturing large numbers of cells. , LCM ...
Hybridizer (220 V) from Dako
...00 System is an automated multiplexing platform th...ing SNP detection, pathogen sequence detection and...ith multiple targets can be applied to an open and...ridge, which may be reused until all tests sites h...
Bio-Plex Manager Version 3.0 to 4.0 Workstation Software Upgrade Kit from Bio-Rad
Biology Products: